Outcomes With Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Myeloid Neoplasms: A Systematic Review and Meta-Analysis Publisher Pubmed



Shahzad M^{1, 2} ; Amin MK³ ; Khalid MF⁴ ; Kasaeian A^{5, 6} ; Oskouie IM⁷ ; Yu J^{1, 2} ; Warraich SZ⁸ ; Basharat A⁹ ; Butt A¹⁰ ; Zaidi M¹¹ ; Anwar I³ ; Jaglal MV^{1, 2} ; Mushtaq MU³ Show Affiliations
Source: Clinical Lymphoma, Myeloma and Leukemia Published:2025

Abstract

Therapy-related myeloid neoplasms (t-MN), which include acute myeloid leukemia (t-AML), myelodysplastic syndrome (t-MDS), and myelodysplastic/myeloproliferative neoplasms are secondary malignancies occurring as a late complication following chemotherapy or radiation therapy for an antecedent disorder. Allogeneic hematopoietic stem cell transplant (allo-HCT) is a potentially curative treatment option in t-MN patients. This systematic review and meta-analysis aimed to explore the outcomes of allo-HCT in t-MN. Following PRISMA guidelines, a comprehensive literature search was performed on PubMed, Cochrane, and Clinicaltrials.gov. Survival data were extracted from Kaplan–Meier curves to calculate overall survival (OS) and disease-free survival (DFS) probabilities. A total of 7785 (t-AML: 67.3%, t-MDS: 26.5%, and mixed presentation: 6%) patients from 33 original studies reporting outcomes of allo-HCT in t-MN patients were included for analysis. The patients age ranged from 2 to 89 years, and 61.7% were female. The pooled median OS was 16.9 months (95% CI: 13.7-21.1), whereas the estimated mean OS was 46.0 months (95% CI: 42.1-49.6). The pooled median DFS was 8.8 months (95% CI: 7.4-11.2), and the mean DFS was 35.5 months (95% CI: 33.4-41.9). The pooled proportion of acute graft-versus-host disease (aGvHD) was 34% (95% CI: 0.35-0.45, I²: 91.71%, P < .0001). Relapse of the myeloid neoplasm was the most common cause of mortality, followed by infections, relapse of the underlying disease, and GvHD. Despite these challenges, allo-HCT remains a potential treatment option with promising outcomes for carefully selected t-MN patients. © 2025 Elsevier Inc.